New pill takes on Hard-to-Treat prostate cancer in early human trial

NCT ID NCT06801236

Recruiting now Disease control Sponsor: Acerand Therapeutics (Hong Kong) Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new daily pill called ACE-232 in 67 men with metastatic castration-resistant prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it might help control the cancer. Participants will also take two other medicines (dexamethasone and fludrocortisone) alongside ACE-232.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ACE-232 tablets taken daily with dexamethasone and fludrocortisone
What this could lead to: If this early trial shows promise, it could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 study with only 67 participants, focused mainly on safety and dosing. It is too soon to know if ACE-232 will work or be safe enough for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRPC, METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC, METASTATIC CASTRATION RESISTANT PROSTATE CANCER PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109, United States
Harvard Medical School-Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
M Health Fairview Clinics and Surgery Center
RECRUITING

Minneapolis, Minnesota, 55455, United States
Moffitt Cancer Center, Tampa
RECRUITING

Tampa, Florida, 33612, United States
University of California San Diego, Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States
University of Maryland, Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
Xcancer (Urology Cancer Center)
RECRUITING

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.